One of the major market trends is the increasing prevalence of ATTR-CM. As per studies, the prevalence of ATTR-CM is estimated to be 50,000-100,000 cases in the United States and similar trends have been observed in the European region as well. The rising disease incidence can be attributed to numerous factors like increasing elderly population who are at higher risk of ATTR-CM and improved diagnostic capabilities. Additionally, recent approvals and launch of novel drug therapies for ATTR-CM treatment has expanded the market size significantly. For instance, in 2019, USFDA approved patisiran (Onpattro) and tafamidis (Vyndaqel) for transthyretin amyloid cardiomyopathy (ATTR-CM) indication. This has provided novel treatment options to patients and drove the market growth over the forecast period.

Porter's Analysis

Threat of new entrants: The TTR amyloid cardiomyopathy treatment market requires high R&D investments and regulatory approvals lowering the threat of new entrants.

Bargaining power of buyers: The bargaining power of buyers is high due to the availability of alternative treatment options for heart diseases.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to the presence of a large number of suppliers and raw material providers in the market.

Threat of new substitutes: Threat of substitutes is moderate as other treatment options provide comparable health benefits.

Competitive rivalry: High due to the presence of major companies investing in the development of novel treatment drugs.

SWOT Analysis

Strength: Availability of advanced treatment alternatives and strong pipeline of drug candidates. Increasing research on gene therapy and RNA interference opens new opportunities.

Weakness: High costs associated with R&D of new drugs. Requirement of large patient cohorts for clinical trials.

Opportunity: Growing geriatric population susceptible to amyloidosis and cardiovascular diseases. Increasing awareness about early diagnosis.

Threats: Stringent regulatory approvals. Reimbursement issues in some regions pose commercialization challenges.


Key Takeaways

The Global Transthyretin Amyloid Cardiomyopathy Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.% over the forecast period, due to increasing prevalence of hereditary TTR amyloidoses.

Read Our More Blogs : https://www.zupyak.com/p/3930588/t/gene-therapy-is-fastest-growing-segment-fueling-the-growth-of-transthyretin-amyloid-cardiomyopathy-treatment-market